ArticleStem cells international2026
Amentoflavone Suppresses Stemness of Retinoblastoma Cell via Targeting Smoothened (SMO) Protein.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amentoflavone Suppresses Stemness of Retinoblastoma Cell via Targeting Smoothened (SMO) Protein.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma (RB), a malignant intraocular tumor, represents a critical public health challenge, particularly for pediatric populations, underscoring the urgent need for innovative therapeutic approaches and novel drug development. In this study, amentoflavone (AMF) was identified as a potential agent against RB cancer stem cells (RBCSCs). While CCK8 assays revealed moderate anti-proliferative effects of AMF on RB cell lines, migration and invasion assays demonstrated its potent ability to suppress cancer cell motility. Tumorsphere formation assays further indicated that AMF significantly reduces RB cell stemness. qRT-PCR analysis showed that AMF downregulates expression of stem cell markers (CD44, CD133, Oct4, and Nanog) in a dose-dependent manner. In vivo studies confirmed that AMF inhibits tumor metastasis and prolongs survival in RB mouse models. To elucidate its mechanism of action, RNA sequencing, molecular docking, and surface plasmon resonance (SPR) were employed. These analyses revealed that AMF directly targets smoothened (SMO) to disrupt the SHh signaling pathway, thereby suppressing RB stem cell (RBSC) self-renewal and tumor progression. This work uncovers a previously unreported mechanism by which AMF hinders RB development and highlights its potential as a promising therapeutic candidate for this aggressive pediatric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.